Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

The leading malaria vaccine in development is the circumsporozoite (CS) protein-based vaccine, RTS,S, which targets the pre-erythrocytic stage of Plasmodium falciparum infection. It induces modest levels of protective efficacy largely mediated by CS specific antibodies. We aimed to enhance vaccine e...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Gilbert, S, Collins, K, Snaith, R, Cottingham, M, Hill, A
Natura:	Journal article
Pubblicazione:	Nature Publishing Group 2017

Documenti analoghi

Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity
di: Chauveau, L, et al.
Pubblicazione: (2021)

Virus-like particles as vaccine adjuvants.
di: Gilbert, S
Pubblicazione: (2001)

Virus-like particle vaccines
di: Mukhopadhyay, E, et al.
Pubblicazione: (2022)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
di: Schneider, J, et al.
Pubblicazione: (1998)

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
di: Dégano, P, et al.
Pubblicazione: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
di: Moorthy, V, et al.
Pubblicazione: (2003)

Protein particle vaccines against malaria.
di: Gilbert, S, et al.
Pubblicazione: (1997)

The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.
di: de Cassan, S, et al.
Pubblicazione: (2011)

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
di: Ambühl, P, et al.
Pubblicazione: (2007)

Virus-like particle (VLP) plus microcrystalline tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against Plasmodium berghei/vivax
di: Cabral-Miranda, G, et al.
Pubblicazione: (2017)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
di: Gilbert, S, et al.
Pubblicazione: (1999)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
di: Mcshane, H, et al.
Pubblicazione: (2001)

Complete protective immunity against blood-stage malaria induced by heterologous prime-boost vaccination
di: Draper, S, et al.
Pubblicazione: (2005)

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.
di: Moore, A, et al.
Pubblicazione: (2005)

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.
di: Kündig, T, et al.
Pubblicazione: (2006)

Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells.
di: Engeroff, P, et al.
Pubblicazione: (2017)

Evaluation of the immunogenicity of a promising vaccine regimen to identify immune correlates of protection
di: Pinpathomrat, N
Pubblicazione: (2018)

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.
di: Spohn, G, et al.
Pubblicazione: (2005)

The coming of age of virus-like particle vaccines.
di: Jennings, G, et al.
Pubblicazione: (2008)

Immunogenicity of vaccines for malaria-exposed populations
di: Bowyer, GSA
Pubblicazione: (2018)

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
di: Draper, S, et al.
Pubblicazione: (2010)

Preclinical antihypertensive efficacy and immunogenicity in humans of a vaccine against angiotensin II based on virus-like particles (VLPs)
di: Tissot, A, et al.
Pubblicazione: (2005)

Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein
di: Kim, YC, et al.
Pubblicazione: (2024)

Engineering a modular virus-like particle platform for enhanced vaccine assembly
di: Wu, H-J
Pubblicazione: (2022)

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.
di: Gilbert, S, et al.
Pubblicazione: (2002)

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis.
di: Spohn, G, et al.
Pubblicazione: (2008)

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M
di: Venkatraman, N, et al.
Pubblicazione: (2017)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
di: Dicks, M, et al.
Pubblicazione: (2011)

Virus-like particles of macrobrachium rosenbergii nodavirus capsid as a carrier for immunogenic components
di: Tan, Wen Siang, et al.
Pubblicazione: (2014)

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity to bacterial, viral and parasitic antigens: increased durable cellular immunity with reduced immunodominance
di: Moore, A, et al.
Pubblicazione: (2005)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-riming and boosting with adenovirus or protein based vaccines
di: Dean, G, et al.
Pubblicazione: (2014)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
di: Dean, G, et al.
Pubblicazione: (2014)

4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.
di: Spencer, A, et al.
Pubblicazione: (2014)

Virus like particles as a platform for cancer vaccine development
di: Hui, Kian Ong, et al.
Pubblicazione: (2017)

Versatile virus-like particle carrier for epitope based vaccines
di: Tissot, A, et al.
Pubblicazione: (2010)

Virus-like particles as a modular system for novel vaccines.
di: Lechner, F, et al.
Pubblicazione: (2002)

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse
di: Flaxman, A, et al.
Pubblicazione: (2024)

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
di: Bessa, J, et al.
Pubblicazione: (2008)

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
di: Moorthy, V, et al.
Pubblicazione: (2004)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
di: Reyes-Sandoval, A, et al.
Pubblicazione: (2010)